Haemoglobin Levels and Breast Cancer Chemotherapy Response
Author Information
Author(s): Bottini A, Berruti A, Brizzi M P, Bersiga A, Generali D, Allevi G, Aguggini S, Bolsi G, Bonardi S, Bertoli G, Alquati P, Dogliotti L
Primary Institution: Azienda Ospedaliera Istituti Ospitalieri, Cremona, Italy
Hypothesis
Baseline haemoglobin levels significantly predict the tumour response to primary chemotherapy in breast cancer patients.
Conclusion
The study found that lower baseline haemoglobin levels are associated with poorer tumour response to chemotherapy in breast cancer patients.
Supporting Evidence
- 154 patients were evaluated for their baseline haemoglobin levels and chemotherapy response.
- The overall response rate to chemotherapy was 72.1%.
- Patients with higher baseline haemoglobin levels had better treatment outcomes.
Takeaway
If a breast cancer patient has low haemoglobin levels, they might not respond as well to chemotherapy. It's like needing enough fuel to run a car; without it, the car won't go far.
Methodology
The study evaluated 154 breast cancer patients' baseline haemoglobin levels and their response to primary chemotherapy, using clinical measurements and statistical analysis.
Potential Biases
Potential biases may arise from the single-institution study design and patient selection.
Limitations
The study was conducted at a single institution and may not be generalizable to all breast cancer patients.
Participant Demographics
The study involved 154 female patients with operable breast tumours, aged between premenopausal and postmenopausal.
Statistical Information
P-Value
p<0.002
Confidence Interval
95% Confidence intervals for haemoglobin levels were reported.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website